SEOM clinical guidelines for treatment of prostate cancer

• Autores: J. A. Arranz Arija, Javier Cassinello Espinosa, Miguel Ángel Climent Durán, Fernando Rivera Herrero
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 14, Nº. 7, 2012, págs. 520-527
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Prostate cancer (PC) is the most common cancer in men. Many patients have prolonged survival and die of other diseases, so treatment decisions are often influenced by age and coexisting comorbidities. The main procedure to diagnose PC is an ultrasound-guided core needle biopsy, which is indicated when a digital rectal examination (DRE) finds nodularity or when PSA is >10 ng/ml, but is also recommended with PSA between 4.0 and 10 ng/ml. Depending on age, PSA, Gleason score and characteristics of the tumour, treatment options for localised PC are active surveillance, radical prostatectomy and radiation therapy. Androgen deprivation treatment (ADT) should be added to radiotherapy for men with intermediate- or high-risk PC. ADT is the current standard first-line treatment for metastatic PC. Castration-resistant PC is a heterogeneous entity. Several treatments such as sipuleucel-T, docetaxel-based chemotherapy, radium 223, cabazitaxel or abiraterone plus prednisone, zoledronic and denosumab, are useful for this situation.